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There is a growing interest amongst clinical investiga-
tors in the conduct of single trials combining the safety
exploration of phase I with the initial investigations of
efficacy usually made during phase II. This is being
made increasingly possible through the use of biomar-
kers that show early signs of physiological changes that
are associated with a therapeutic effect. Such a com-
bined study calls for complex statistical models, able to
capture the joint distribution of the safety and efficacy
outcomes. Bayesian models are particularly attractive in
such early phase studies because in interpreting small
data sets, judicious use of investigators’ opinions
becomes worthwhile.
We will describe a dose escalation procedure for a
combined phase I/II clinical trial, based on a Bayesian
model for the joint distribution of toxicity and efficacy
(both considered binary variables) making no assump-
tions other than monotonicity: that is the risk of toxicity
and the chance of benefit are both assumed to be non-
decreasing as functions of dose level. The procedure will
be discussed in the context of a placebo-controlled,
sequential trial in rheumatoid arthritis, in which
patients, in each stage, are randomized across all doses
levels that appear safe and non-futile at the time of
recruitment. The primary efficacy outcome is a binary
response at 16 weeks related to an assessment known as
the ACR20, but an earlier efficacy assessment based on
the ACR20 assessment and reduction in C-reactive pro-
tein at 4 weeks is used during the dose escalation phase
for making decisions on doses for the next cohort. The
m e a s u r eo fs a f e t yi st h eo c c u r r e n c eo fad o s el i m i t i n g
toxicity within 4 weeks of treatment. Based on data
from a pilot study, we constructed five different scenar-
ios for the dose-response relationships for which we
simulated the trial and assessed the performance of the
procedure. The new method appears to have satisfactory
operational characteristics, and is flexible in that it can
be adapted to the logistics of a particular trial and incor-
porate a placebo arm.
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